Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma.
Diagn Imaging Clin Med
; 54(1): 21-7, 1985.
Article
en En
| MEDLINE
| ID: mdl-3918823
Total-body scintigraphy with 131I-meta-iodobenzylguanidine (131I-MIBG) was performed in 20 patients with neuroblastoma. In patients who were in complete remission no pathological concentration of 131I-MIBG was found. In 16 patients with residual, recurrent or metastatic neuroblastoma the tumor localizations were correctly identified by 131I-MIBG-scintigraphy In 5 patients additional tumor sites were found. In most patients an inverse relationship between myocardial and tumoral concentration of 131I-MIBG was noted. Dosimetric assessment of 131I-MIBG uptake in patients with metastatic disease revealed cases with considerable tracer concentration and long effective half lives in tumor localizations. It is concluded that 131I-MIBG total-body scintigraphy is useful in the diagnosis and follow-up of neuroblastoma and that therapeutic use of this agent is feasible, if patients are selected upon the merits of dosimetry.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Simpaticolíticos
/
Recuento Corporal Total
/
Radioisótopos de Yodo
/
Yodobencenos
/
Neoplasias Abdominales
/
Neuroblastoma
Tipo de estudio:
Diagnostic_studies
Límite:
Adult
/
Child
/
Child, preschool
/
Female
/
Humans
/
Infant
/
Male
Idioma:
En
Revista:
Diagn Imaging Clin Med
Año:
1985
Tipo del documento:
Article
Pais de publicación:
Suiza